UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM8-A
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR 12(g) OF THE
SECURITIES EXCHANGE ACT OF 1934
Medtronic Global Holdings S.C.A.
(Exact name of registrant as specified in its charter)
| Luxembourg | 98-1202865 | |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |
3b, Boulevard Prince Henri L- 1724, Luxembourg Grand Duchy of Luxembourg | ||
| (Address of principal executive offices) | (Zip Code) | |
Medtronic Public Limited Company
(Exact name of registrant as specified in its charter)
| Ireland | 98-1183488 | |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |
| 20 On Hatch, Lower Hatch Street Dublin 2 Ireland | ||
| (Address of principal executive offices) | (Zip Code) | |
Medtronic, Inc.
(Exact name of registrant as specified in its charter)
| Minnesota | 41-0793183 | |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
710 Medtronic Parkway Minneapolis, Minnesota | 55432 | |||
| (Address of principal executive offices) | (Zip Code) | |||
Securities to be registered pursuant to Section 12(b) of the Act:
Title of each class to be so registered | Name of each exchange on which each class is to be registered | |||
0.00% Senior Notes due 2022 0.25% Senior Notes due 2025 1.00% Senior Notes due 2031 1.50% Senior Notes due 2039 1.75% Senior Notes due 2049 | New York Stock Exchange LLC | |||
If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box. ☒
If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box. ☐
Securities Act registration statement file number to which this form relates: 333-215895
(If applicable)
Securities to be registered pursuant to Section 12(g) of the Act: None
INFORMATION REQUIRED IN REGISTRATION STATEMENT
Medtronic Global Holdings, S.C.A. (“Medtronic Luxco”), Medtronic Public Limited Company (“Medtronic plc”), and Medtronic, Inc. (“Medtronic, Inc.” and together with Medtronic Luxco and Medtronic plc, the “Registrants”) have filed with the Securities and Exchange Commission (the “Commission”) pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Securities Act”), a prospectus supplement, dated June 25, 2019 (the “Prospectus Supplement”), and the accompanying prospectus, dated February 3, 2017 (the “Base Prospectus”). The Prospectus Supplement relates to the issuance and sale by Medtronic Luxco of €250,000,000 principal amount of its Floating Rate Senior Notes due 2021 (the “Floating Rate Notes”), €750,000,000 principal amount of its 0.00% Senior Notes due 2022 (the “2022 Notes”), €1,000,000,000 principal amount of its 0.25% Senior Notes due 2025 (the “2025 Notes”), €1,000,000,000 principal amount of its 1.00% Senior Notes due 2031 (the “2031 Notes”), €1,000,000,000 principal amount of its 1.50% Senior Notes due 2039 (the “2039 Notes”) and €1,000,000,000 principal amount of its 1.75% Senior Notes due 2049 (the “2049 Notes”, and together with the Floating Rate Notes, the 2022 Notes, the 2025 Notes, the 2031 Notes, and the 2039 Notes, the “Notes”). The Notes will be fully and unconditionally guaranteed by Medtronic plc and Medtronic, Inc. The Base Prospectus forms a part of the Registrants’ Registration Statement on FormS-3 (FileNo. 333-215895), filed with the
Commission on February 6, 2017. The Floating Rate Notes were previously registered pursuant to Form8-A filed on March 7, 2019.
Item 1. Description of Registrant’s Securities to be Registered.
The information required by this item is incorporated by reference to the information contained in the sections captioned “Description of Notes” in the Prospectus Supplement and “Description of Debt Securities of Medtronic Global Holdings S.C.A.” in the Base Prospectus. Copies of such descriptions will be filed with the New York Stock Exchange.
Item 2. Exhibits.
Exhibit No. | Description | |
| 4.1 | Base Indenture, dated as of as March 28, 2017, among Medtronic Global Holdings S.C.A., Medtronic, Inc. and Medtronic plc and Wells Fargo Bank, N.A., as trustee (“Medtronic Luxco Senior Indenture”) (incorporated by reference to Exhibit 4.1 to Medtronic plc’sForm 8-K, filed on March 28, 2017) | |
| 4.2 | Third Supplemental Indenture to Medtronic Luxco Senior Indenture, dated as of July 2, 2019 between Medtronic plc, Wells Fargo Bank, N.A. as trustee, and Elavon Financial Services DAC (incorporated by reference to Exhibit 4.1 to Medtronic plc’sForm 8-K, filed on July 2, 2019) | |
| 4.3 | Agency Agreement, dated as of July 2, 2019, between Medtronic Luxco, Wells Fargo Bank, N.A., as trustee, Elavon Financial Services DAC, as paying agent, and U.S. Bank N.A., as transfer agent and registrar | |
SIGNATURE
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, as amended, each Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.
| MEDTRONIC GLOBAL HOLDINGS S.C.A., | ||||
| a Luxembourg corporate partnership limited by shares (société en commandite par actions) represented by Medtronic Global Holdings GP S.à r.l. its general partner, in turn acting by | ||||
| By: | /s/ Erik De Gres | |||
| Name: | Erik De Gres | |||
| Title: | Managing Director and authorized signatory | |||
| MEDTRONIC PUBLIC LIMITED COMPANY | ||||
| By: | /s/ Karen L. Parkhill | |||
| Name: | Karen L. Parkhill | |||
| Title: | Executive Vice President and Chief Financial Officer | |||
| MEDTRONIC, INC. | ||||
| By: | /s/ Karen L. Parkhill | |||
| Name: | Karen L. Parkhill | |||
| Title: | Executive Vice President and Chief Financial Officer | |||
Dated: July 2, 2019
